Saturday, August 2, 2025 8/2/2025

Sudden Death Risk Assessment and Mechanistic Insights in Arrhythmic Mitral Valve Prolapse Using Cardiac MRI and Circulating Proteomic Biomarkers

Award Number: R01HL171150
ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)
PERIOD OF PERFORMANCE START DATE: 09/05/2024
PERIOD OF PERFORMANCE END DATE: 06/30/2029

Group Awards By:

View Award Description

Sudden Death Risk Assessment and Mechanistic Insights in Arrhythmic Mitral Valve Prolapse Using Cardiac MRI and Circulating Proteomic Biomarkers - Project Summary: Mitral valve prolapse (MVP) is a common valvulopathy affecting 2-3% of the population and nearly 200 million individuals globally. While it is often benign, a subset of patients with MVP may develop arrhythmias, including sudden cardiac death (SCD). Although the association between MVP and SCD was first reported decades ago, the risk was initially believed to be small; contemporary observational studies suggest that SCD may be a more common sequela in MVP, with an estimated yearly incidence between 0.4 and 1.9%. The National Heart, Lung, and Blood Institute recently convened a workshop composed of subject matter experts and stakeholders to identify research needs and opportunities to develop recommendations for the identification and treatment of individuals with mitral valve prolapse, including such individuals who may be at risk for sudden cardiac arrest or sudden cardiac death. Our current proposal is designed to align closely with the priorities identified in the recent NIHBI workshop. Specifically, our proposal has three aims: 1) perform deep phenotyping of patients with MVP to understand characteristics and mechanisms associated with ventricular arrhythmias; 2) Study a blood biomarkers panel (including FDA-approved and novel high throughput proteomic markers) that could be used as a sensitive, costeffective screening strategy to identify MVP patients with myocardial fibrosis who are at risk for SCD; 3) Build a novel SCD risk prediction model in MVP inclusive of CMR evidence of myocardial fibrosis by assembling a large observational multicenter MVP registry with over 2,000 contrast-enhanced CMRs and longitudinal follow-up for arrhythmic events.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2025 ( Subtotal = $1,442,069 )
2025	2025	METHODIST HOSPITAL, THE	6670 BERTNER AVE	HOUSTON	TX	77030	HARRIS	USA	Cardiovascular Diseases Research	000	2	6/27/2025	NON-COMPETING CONTINUATION	$1,442,069
														Subtotal = $1,442,069

Issue Date FY: 2024 ( Subtotal = $1,518,070 )
2024	2024	METHODIST HOSPITAL, THE	6670 BERTNER AVE	HOUSTON	TX	77030	HARRIS	USA	Cardiovascular Diseases Research	000	1	9/5/2024	NEW	$1,518,070
														Subtotal = $1,518,070

Grand Total All Awards = $2,960,139

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Sudden Death Risk Assessment and Mechanistic Insights in Arrhythmic Mitral Valve Prolapse Using Cardiac MRI and Circulating Proteomic Biomarkers

Award Number: R01HL171150

ORGANIZATION: NATIONAL HEART, LUNG, & BLOOD INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: SCIENTIFIC/HEALTH RESEARCH (INCLUDES SURVEYS)

PERIOD OF PERFORMANCE START DATE: 09/05/2024

PERIOD OF PERFORMANCE END DATE: 06/30/2029

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer